A long Covid collaborative kicks off with $15M to study causes of lingering disease, conduct clinical trials

The Covid-19 pandemic has left millions of people with lingering symptoms months after initial diagnosis, and none of the handful of biopharmas that have attempted to treat the so-called long Covid have succeeded yet.

A new collaboration — bringing together researchers from leading institutes in academia — will hone in on what the virus does to “drive chronic disease,” research how SARS-CoV-2 affects the immune system and what effects it could have on cognitive function, nerve signaling and other processes. The group also wants to dig into the root cause of the disease.